Baiseng Medicine (301096.SZ): BIOS2242 oral solution approved for clinical trials.

The Wisdom Finance APP reported that Baicheng Pharmaceutical (301096.SZ) has announced that its wholly-owned subsidiary, Zhejiang Saimo Pharmaceutical Co., Ltd. ("Saimo Pharmaceutical"), recently received a clinical trial approval notification from the National Medical Products Administration (NMPA) for the drug BIOS2242 oral solution. After review, the clinical trial application for BIOS2242 oral solution, which was submitted on August 27, 2025, meets the relevant requirements for drug registration. The NMPA has approved the clinical trial for the indication of "treatment of mild to moderate acute ischemic stroke" for this product.